Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory waldenström macroglobulinemia

Irene M. Ghobrial, Morie Gertz, Betsy LaPlant, John Camoriano, Suzanne Hayman, Martha Lacy, Stacey Chuma, Brianna Harris, Renee Leduc, Meghan Rourke, Stephen M. Ansell, Daniel DeAngelo, Angela Dispenzieri, Leif Bergsagel, Craig Reeder, Kenneth C. Anderson, Paul G. Richardson, Steven P. Treon, Thomas E. Witzig

Research output: Contribution to journalArticle

108 Scopus citations

Fingerprint Dive into the research topics of 'Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory waldenström macroglobulinemia'. Together they form a unique fingerprint.

Medicine & Life Sciences